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Abstract:
            Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice.
Neither the natural history of AF nor its response to therapy are sufficiently predictable by
clinical and echocardiographic parameters. 
               Atrial fibrillatory frequency (or rate) can reliably be assessed from the surface
electrocardiogram (ECG) using digital signal processing (filtering, subtraction of averaged
QRST complexes, and power spectral analysis) and shows large inter-individual variability. This
measurement correlates well with intraatrial cycle length, a parameter which appears to have
primary importance in AF domestication and response to therapy. AF with a low fibrillatory rate
is more likely to terminate spontaneously, and responds better to antiarrhythmic drugs or
cardioversion while high rate AF is more often persistent and refractory to therapy. 
            In conclusion, frequency analysis of AF seems to be useful for non-invasive assessment
of electrical remodeling in AF and may subsequently be helpful for guiding AF therapy.
Key words: atrial fibrillation – ECG signal processing – electrical remodeling – antiarrhythmic
drug monitoring – cardioversion.
            In recent years, mechanisms leading to atrial fibrillation (AF) induction and maintenance
have begun to be explored and rapidly evolving therapies including new antiarrhythmic drugs,
antitachycardia pacing algorithms and catheter ablation techniques have been introduced in
clinical practice. Nevertheless, outcome of AF patients is still unsatisfactory which - to the
greatest extent - can be attributed to the progressing nature of this arrhythmia and high AF
recurrence rates following restoration of sinus rhythm. Moreover, AF treatment (e.g. rate vs.
rhythm control, choice of antiarrhythmic drugs or device therapy, curative ablation) may be
viewed as being based on trial and error, since no test is able to predict the natural history of this
arrhythmia or its response to treatment. Subsequently, current AF management guidelines1
provide no treatment recommendations that “take the various mechanisms and patterns of AF
into account”. Thus, it seems desirable to develop tests that quantify AF disease state and guide
AF management2.
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               Virtually in every patient with AF, a standard surface electrocardiogram (ECG) is
acquired, the main purposes being confirmation of arrhythmia presence and determination of
ventricular rate. Fibrillation waves have, moreover, various appearances ranging from fine to
coarse and from disorganized to organized, flutter-like. Interestingly, the mechanisms behind the
various appearances of the fibrillatory process on the ECG and the possible prognostic
information contained within fibrillation waves have just very recently begun to be explored. 
            The aim of this article is twofold; (1) to describe novel frequency analysis techniques of
the surface ECG for characterization of the fibrillatory process, and (2) to present possible
applications of these methods, namely for (a) exploring autonomic modulation of AF, (b)
monitoring and predicting antiarrhythmic drug effects,  and  (c) predicting AF recurrence
following restoration of sinus rhythm. For this purpose, Medline-listed, peer-reviewed studies
are included in this review.
Rationale for Using Atrial Fibrillatory Rate to Characterize Human AF
               Shortening of atrial refractoriness and maladaptaion to rate are hallmarks of atrial
electrical remodeling in AF3. During AF, re-excitation occurs during the repolarization phase of
the preceding electrical wave, implying that local excitation almost always occurs without any
obvious latency beyond the refractory period. Subsequently, the average atrial fibrillatory rate is
likely to reflect averaged refractoriness at any part of the tissue involved. This assumption has
been independently verified in both animal4 and human AF5,6. Hence, the length of the averaged
atrial fibrillatory cycle (which is inversely related to fibrillatory frequency or rate) can be used as
an index of the averaged atrial myocardial refractoriness and subsequently AF organization7. The
importance of shortened refractoriness and subsequently its transformation into short atrial
cycles or high rates as assessed by direct intraatrial measurements for AF progression and
response to therapy has been well established. Results will be reported as cycle length in
milliseconds (ms) if they were obtained from intraatrial recordings. If they were obtained from
surface recordings, they will be reported as fibrillatory rate in fibrillations per minute (fpm, the
rationale to use this expression is discussed in depth below).
            Firstly, spontaneous arrhythmia behavior is related to baseline fibrillatory cycle length.
Asano et al induced AF with rapid pacing in 30 patients undergoing electrophysiologic study8.
Patients in whom AF terminated spontaneously (n=20) had an average fibrillatory cycle lenghth
of 176 ms (341 fpm), significantly lower than the 157 ms (382 fpm) recorded in the group of
patients where the arrhythmia persisted (n=10). Similar observations were made by Boahene et al
who also measured the fibrillatory cycle length from the right atrium in 55 patients with Wolff-
Parkinson-White syndrome9. These investigators also found that patients with sustained AF
(n=45) had shorter mean cycle lengths compared to patients with non-sustained AF (n=10). 
            Secondly, response to antiarrhythmic drug therapy has been shown to be associated with
baseline cycle length and drug-induced cycle length changes. Stambler and colleagues identified
a mean right atrial cycle length of 160 ms (375 fpm) as a valuable cutoff-point for conversion to
sinus rhythm with ibutilide10. No patient with shorter cycle length (higher rate) was converted by
ibutilide, whereas conversion occured in 64 % of those patients with longer cycle length (lower
rate). Similarly, Fujiki et al 11 by using spectral analysis of right atrial electrograms reported 100
% AF conversions with cibenzoline or procainamide if the baseline atrial cycle length was > 168
ms (< 357 fpm) as opposed to only 17 % in patients with shorter cycle lengths (higher rates).
Moreover, AF conversion was associated with cycle length prolongation. AF terminated after
class I drug administration in 88 %, if the atrial cycle length had been prolonged to > 210 ms (<
285 fpm), in contrast to only 10 % if the post-drug cycle length was shorter.
               Finally, there exists a close relation between the degree of electrical remodeling
expressed as refractoriness changes and AF recurrence following cardioversion. Manios et al
found that patients who failed to shorten the monophasic action potential duration to less then
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195 ms at a pacing cycle length of 350 ms were more likely to have AF recurrence12. This
finding was explained by a more abnormal rate adaptation curve, which is in agreement to an
early study performed by Attuel and colleagues showing that poor or absent rate adaptation of
atrial refractory periods (that is, the normally close correlation between stimulation cycle length
and refractory period was lost) is related with vulnerability to AF13. These findings have more
recently been replicated in patients undergoing internal cardioversion14. In their study, Biffi et al
identified   both   a   shorter   atrial   effective   refractoriness   and   abnormal   rate   adaptation   as
independent predictors for AF relapses, the latter being the strongest predictor.
               Prompted by the likely usefulness of non-invasive test that assesses the average
fibrillatory  rate   from   the   surface   ECG   for   exploration   of   AF  pathophysiology  and   AF
managment, frequency analysis techniques were independently introduced by our groups15,16,
while two earlier studies proposed to use this technique to subdivide AF and atrial flutter17 or
automatically identify AF among different rhythms 18. 
Frequency Analysis Techniques
Methodological Considerations
            
            Using digital recording techniques, traditional ECG signals are recorded. In most studies
atrial fibrillatory rate has been obtained by spectral analysis techniques of resting ECG
recordings such as standard 12-lead15,16 or (modified) orthogonal recordings19,20,21. The method
has, however, also been applied to ambulatory ECG recordings using conventional ambulatory
leads22,23,24.
            The accuracy of frequency analysis techniques strongly relies on the fact that the largest
possible fibrillatory waves should be present for further signal processing. Therefore, it was
suggested to analyze lead V1 when using a standard ECG or, as proposed previously by Waktare
et al25, a “bipolar modification of V1” covering the atria (low C1) when applying different ECG
recording systems (e.g. Holter ECG)20.
            Since the atrial and ventricular activities overlap spectrally, linear filtering techniques are
not suitable for extraction of the fibrillatory signal from the surface ECG. Instead, subtraction of
averaged QRST complexes needs to be performed producing a remaining atrial fibrillatory signal
for further analysis (Figure 1). Originally, a fixed averaged QRST-complex was used for
cancellation in individual leads. Further development of the method allowed an improved
cancellation of the QRST-complex by taking changes in QRS morphology due to alterations in
the electrical axis of the heart into account (spatiotemporal QRST cancellation)26. 
            Following QRST cancellation, a power spectrum is obtained by using a windowing
technique and Fourier analysis to process the remainder ECG. This as well as the associated
windowing technique (window type, length and overlap) determine the appearance of the
frequency   power   spectrum15.   Variants   of   Fourier   transform   based   methods   including
conventional Fourier analysis and spectral averaging techniques based on short overlapping
segments have been applied to ECG segments ranging from 10 seconds to 5 minutes15,16,27,28,29.
Typically a distinct spectral peak is obtained which corresponds to the most dominant fibrillatory
rate   of   nearby   endocardial   sites15,16,   but   bi-   or   multimodal   peaks   are   also   sometimes
observed15,30.
            More recently, a time-frequency analysis approach has been developed by which the
time-frequency distribution is decomposed into a number of descriptive functions reflecting
second-to-second variations in fundamental frequency and waveform morphology31,32. The main
advantage of using this approach is that the local signal quality and structure is also assessed.
The spectral profile differs from the conventional spectrum in that the different local spectra
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have been frequency aligned before averaging. This results in more distinct peaks and a more
clearly discernable harmonic structure. With its second-to-second resolution, the method can
rapidly detect changes in frequency, regularity, amplitude, waveform and signal structure and
quality (Figure 1). 
 
Figure 1: Frequency analysis of AF. Two seconds (out of a 60 second recording) of an ECG
signal from a patient with AF (upper panel), and the same interval after QRST cancellation
(middle panel, amplitude scale is magnified five times). This fibrillatory signal is then subjected
to Fourier analysis. Time-frequency distribution (left box), power frequency spectrum in which
the dominant fibrillatory rate is determined (middle box), frequency trend (right box).
            To date, the dominant spectral peak has been presented as either dominating atrial cycle
length (in ms), fibrillatory rate (in fpm) or fibrillatory frequency (in Hz). Since it has become
evident that the results of this method might be of practical clinical importance, we believe that
the results should be expressed in a way which is closest to the nomenclature of other surface
ECG   rate-variables   (e.g.   sinus   rate,   atrial   tachycardia   or   flutter   rate)33.   The   expression
“fibrillatory rate”, with its unit “fibrillations per minute - fpm” may therefore be most
appropriate20. Moreover, the calculation of cycle length from the frequency power spectrum with
its standard unit Hz (cycle length in ms = 1000/frequency in Hz) seems somewhat troublesome34.
While this calculation is appropriate for single measurements, its application to multiple Daniela
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simultaneous or repeated measurements such as pre- and post-drug states may introduce
significant statistical and subsequently scientific errors, especially if the baseline frequency
exhibits large inter-individual variability. The reason is, that the same frequency difference
results in larger cycle length differences for low frequencies compared to high frequencies. 
Method Validation and Reproducibility
              A direct comparison between endocardially recorded electrograms and body surface
recordings clearly evidences the validity of fibrillatory rate obtained from surface ECG as an
index of the average atrial fibrillatory cycle and subsequently atrial refractoriness. Fibrillatory
rates calculated from lead V1 substitute the right atrial free wall15,16  whilst rates from an
oesophageal lead reflect atrial septal and left atrial activity15.  Figure 2  illustrates the close
agreement   of  right   atrial   and  coronary  sinus  fibrillatory  rates  with  rates   obtained  from
simultaneously recorded surface ECG lead V1 in persistent AF. Interestingly, rate differences
and variability between ECG and electrograms increase with growing anatomical distance (right
atrium – coronary sinus – pulmonary veins) to V1. Approximately 50 % of V1 and superior
pulmonary vein rates are also within close range. In the other cases, the latter has been found to
be substantially faster but also slower than V1 (right atrium), indicating that superior pulmonary
veins might not necessarily be the driving source of the fibrillatory process. 
            Although the gross atrial fibrillatory pattern, studied by multiple simultaneous epicardial
recordings, is reproducible already in repeated measurements of only 8 seconds duration35,
calculation of fibrillatory rates during steady state conditions from even longer time intervals
discloses a true variability. Thus, increasingly longer recording times of up to 30 minutes result
in a successive decrease of this variability. The reproducibility of the method is thus enhanced by
prolonging the recording time during steady state conditions, allowing integration of atrial
fibrillatory activity over longer periods. For practical reasons, steady state recordings may be
restricted to one to five minutes, yielding rate variation coefficients of 2.1 %15.
            In persistent AF, there is minor short-term rate variability15,16,27 and considerable diurnal
variability (for details see below)23,24, whilst repeated daily frequency measurements at identical
medication at the same time under similar conditions discloses an insignificant fibrillatory rate
variability 36. In contrast, rate variability in paroxysmal AF seems to be related to its natural
course with a rate increase within the first five minutes of an AF episode22 and a rate decrease
prior to termination22,28. 
Exploring Autonomic Modulation of AF
            Vagal as well as sympathetic stimulation have been shown to reduce atrial refractory
periods and increase their heterogeneity37,38,39. In the human atrium beta stimulation has been
found to predominate over vagal stimulation38. Moreover, invasive studies performed in subjects
with sinus rhythm have suggested a circadian pattern in atrial refractoriness with longer
refractory periods during night time and refractory period shortening during daytime40,41 which
supports the role of the autonomic nervous system in modulating atrial electrophysiologic
properties. Subsequently, atrial fibrillatory rate seems to be ideal for monitoring the effect of
autonomic tone changes – either spontanenous (circadian) or by autonomic maneuvers provoked
– on atrial electrophysiology. Indeed, the circadian variability of atrial fibrillatory rate has been
explored in independent studies23,24. Fibrillatory rate obtained from Holter ECG’s with persistent
AF showed a significant decrease at night and an increase in the morning hours23,24. In 6 out of
30 individuals studied by our group23, dominant nocturnal fibrillatory rate increased, however,
concomitantly with a decrease in ventricular rate, while the opposite change occurred in the
morning hours.
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Figure 2:  Agreement of fibrillatory rates from the right atrium (upper left), coronary sinus
(upper right), superior pulmonary veins (lower) with simultaneously recorded fibrillatory rates
from surface ECG lead V1 (Bland-Altman method).
            The second area of investigation concerns effects on atrial fibrillatory rate following
vagal or  sympathetic  stimulation during  experimental  conditions.  Carotid  sinus  massage,
supposed to mainly induce vagal stimulation, resulted in a variable effect on fibrillatory rate in
19 patients42. A reproducible decrease was noted in 9 individuals, whilst a rate increase occurred
in 8 and no change was observed in two patients. Interestingly, calcium-channel blocker
treatment was the only variable effecting the rate response to carotid sinus massage. Calcium-
channel blockers were more frequently used in patients with a decrease in fibrillatory rate
compared to patients with a rate increase. The effect of adrenergic stimulation via head-up tilting
on fibrillatory rate was studied in 14 patients with long-lasting AF43. In 12 patients head-up
tilting increased fibrillory rate significantly, while there was no rate change in the remaining two.
            With the availability of instantaneous fibrillatory rates obtained from time-frequency
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analysis, their second-to-second variation can be explored by spectral analysis techniques,
similar to those used for analyzing heart rate variability. By applying this approach, Stridh et al44
noted a spectral peak in 2 out of 8 patients with permanent AF at the breathing frequency of
0.125 Hz during controlled respiration that disappeared after atropine injection.
               All these findings together clearly highlight the complexity of autonomous nervous
system effects on atrial electrophysiology and justify further exploration. 
Monitoring and Predicting Antiarrhythmic Drug Effects 
            Class I and III antiarrhythmic drugs have been shown to increase atrial cycle length
(decrease   fibrillatory   rate)   which   coincides   with   increased   refractoriness   and   decreased
conduction velocity45. These mixed effects might explain why atrial cycle length is closely
related with baseline refractoriness6  but not with refractoriness after antiarrhythmic drug
administration46. Even though the individual contribution of refractoriness prolongation or
conduction slowing might currently not be differentiated, monitoring drug action on atrial
fibrillatory rate seems well fit to be explored by analysing the surface ECG. Indeed, a substantial
reduction   in   atrial   fibrillatory   rates   following   several   different   intravenously   or   orally
administered class I and III antiarrhythmic drugs as well as following verapamil or magnesium 
has been observed (Table 1).
Table 1. Summary of available literature on frequency analysis techniques (for details see text). 
Primary 
Investigator
Investigation
Bollmann Olsson Stridh &
 Sornmo
Others
Validation Comparison with
intracardiac EGM
(N=54)16
Comparison with
intracardiac and
esophageal EGM (N=8)
15
Comparison with
asystolic ECG segment
(N=12)27
Method improvement Spatiotemporal QRST
cancellation26
Time-frequency
analysis31,32
Reproducibility Short-term (N=6)16 Short-term (N=10)15
Long-term (N=10)36
Short-term (N=5)27
Circadian rate variation Every 6 hours (N=30)23Every hour (N=20)24
Spontaneous AF
termination
Onset vs. mid-episode
vs. termination (N=11)
22
10 min before
termination vs.
termination (N=19)28 
Monitoring and
predicting atrial drug
effects
i.v. ibutilide (N=15)16
p.o. amiodarone (N=5)
22
p.o. sotalol (N=3)22
p.o. flecainide (N=18)19
p.o. verapamil (N=27)62
i.v. sotalol (N=5)15
p.o. verapamil (N=10)36
i.v. MgSO4 (+GIK)
(N=13)63
i.v. cibenzoline (N=5)28
i.v. procainamide (N=3)
28
p.o. bepidril (N=22)29
i.v. ibutilide (N=19)64
Monitoring autonomic
maneuvers
Carotid sinus massage
(N=19)42
Head-up tilt test (N=14)
43
Controlled breathing +
i.v. atropine  (N=8)44
Predicting ADFT Internal CV (N=19)57 External CV (N=29)58
Predicting AF
recurrence
Internal CV (N=19)57
External, internal or
drug-induced CV
(N=44)21
Heart rhythm
differentiation
Sinus rhythm vs. atrial
fibrillation
18
CV = cardioversion, EGM = electrogram, GIK = glucose, insulin, potassium, ADFT = atrial
defibrillation threshold
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            Two examples of drug monitoring are presented in Figure 3 showing the transition from
a high rate (less organized) to a low rate (more organized) fibrillation following acute
intravenous sotalol infusion or 3-day oral flecainide administration.
 
 
Figure 3:  Examples of antiarrhythmic drug monitoring. Atrial fibrillatory rate obtained
from time-frequency-analysis during  intravenous infusion of dl-sotalol. The solid
black colour indicates the actual fibrillatory rate. Initially, the atrial rate is at the level of
390 fpm (6.5 Hz), but decreases successively to the level of 330 fpm (5.5 Hz) during 20
minutes (upper panel). Time-Frequency-analysis at baseline (middle) and after 3-days
oral flecainide intake (bottom). Frequency power spectrum (left) and frequency trend
(right). Please note the more pronounced dominant and harmonic peaks after drug
administration as well as atrial rate reduction and rate stabilization.
               Besides direct monitoring of antiarrhythmic drug effects, it seems also possible to
identify suitable patients for pharmacological cardioversion. A baseline fibrillatory rate of 360
fpm was highly sensitive and specific for prediction of AF termination following intravenous
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ibutilde16 or oral flecainide19 (Figure 4). In contrast, Fujiki et al noted no baseline fibrillatory
rate difference between patients who converted to sinus rhythm and those who did not following
oral bepridil administration. Instead, larger rate increases were associated with AF termination.
While this concept is interesting and well established in experimental AF45, it needs to be
emphasized that these authors calculated atrial cycle length from the frequency spectrum, which
may have introduced the aforementioned statistical errors34.
 
Figure 4: Relation between baseline fibrillatory rate and response to intravenous ibutilide (left)16
and oral flecainide (right)19. AF with slower rates is more likely to respond to antiarrhythmic
drug therapy, while faster rates are more often found in drug-refractory AF. 
               Patients with a low fibrillatory rate may have a small number of wavelets (long
wavelength), whereas those with higher rates have multiple wavelets (short wavelength)7. In the
former group class I or III antiarrhythmic drugs by decreasing fibrillatory rate may have
increased wavelength (or the excitable gap) and therefore reduced the number of wavelets that
could coexist. This would have increased the statistical chance that all wavelets might extinguish
simultaneously and terminate the fibrillatory process47. 
          One previous study suggested that a stepped conversion regimen of first-line ibutilide
followed by electrical cardioversion for patients who fail to convert is less expensive and has a
higher   conversion   rate   than   first-line   electrical   cardioversion48.   Given   the   expense   of
antiarrhythmic therapy and the risk of side effects including ventricular proarrhythmia, a test that
differentiates responders from non-responders is likely to be even more cost-effective. In
addition, drug monitoring using frequency analysis techniques may be useful for finding optimal
drug dosages and timing of interventions in the individual patient.
Predicting AF Recurrence
            Previous investigations49,50 have shown that most AF relapses occur within the first
weeks   after   cardioversion   with   decreased   but   constant   recurrence   rates   thereafter.   Early
vulnerability to AF re-initiation within this time period is related to electrophysiological
abnormalities, while structural abnormalities seem to be primarily responsible for later AF
recurrences51. This time course might be explained by the fact that reversal of the electrical
remodeling process occurs rapidly once sinus rhythm is restored12,52,53, while structural changes
persist for longer periods51. Subsequently, characterization of atrial electrophysiology has been
suggested for identification of patients at risk for early AF recurrence2.
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            Atrial premature beats with short coupling intervals have been shown to promote early
AF reinitiation following cardioversion54,55. AF reinduction by an atrial premature beat relies on
the fact that a relatively short atrial wavelength (conduction velocity x refractory period) must be
present56. As highlighted before, atrial fibrillatory rate reflects atrial refractoriness5,6, and might
subsequently represent a marker for early AF susceptibility following restoration of sinus
rhythm. Indeed, previous studies reported higher rates in relapsed patients immediately prior
internal57 or external cardioversion21 when compared with non-relapsed patients and also close
relationships between fibrillatory rate and defibrillation thresholds57,58. 
            Two previous studies21,59 have investigated the combined predictive value of fibrillatory
rate and echocardiographic left atrial parameters. In one study59, the authors calculated an index
combining shortest cycle length from oesophageal or V1 lead and standard left atrial diameter
and were able to show that patients with recurring AF had significantly lower values than
patients who remained in sinus rhythm. Another study21 demonstrated that the combination of
fibrillatory rate and systolic left atrial area predicted early AF recurrence after succesful
cardioversion with a high accuracy and was able to provide individual risk estimates (Figure 5). 
 
Figure 5: Outcome following cardioversion stratified by an “electromechanical index” (EMI)
according to the regression equation (EMI = 0.176 systolic left atrial area + 0.029 fibrillatory rate
– 17.674)21.
            These parameters seem therefore well suited to describe the individual atrial remodeling.
The concept of ECG-guided cardioversion may gain even greater importance in the light of
previous findings from two studies comparing rate- with rhythm-control strategies60,61. In these
studies, rhythm-control seemed not to be superior than rate-control in asymptomatic, mostly
eldery patients with recurring AF and structural heart disease. This highlights the need to select
candidates for cardioversion not only based on clinical judgement but also on measures that are
able to determine the likelihood of maintaining sinus rhythm such as rate parameters obtained
from the surface ECG.
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Conclusions
            Atrial fibrillatory rate and its variability can be reliable obtained from the surface ECG in
AF   patients   using   spectral   analysis   techniques.   These   parameters   exhibit   a   significant
interindividual variability allowing individual quantification of the atrial electrical remodeling
process. Frequency analysis of AF might prove useful in identification of underlying AF
pathomechanisms, and prediction of therapy efficacy (drug-induced conversion, maintenance of
sinus rhythm, selecting antiarrhythmic drugs, identifying candidates for non-pharmacological AF
therapy). Further larger studies are necessary to determine the role of these techniques in
different AF management strategies in order to select and time the appropriate therapy for the
individual patient.
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